JP2015531397A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531397A5
JP2015531397A5 JP2015535742A JP2015535742A JP2015531397A5 JP 2015531397 A5 JP2015531397 A5 JP 2015531397A5 JP 2015535742 A JP2015535742 A JP 2015535742A JP 2015535742 A JP2015535742 A JP 2015535742A JP 2015531397 A5 JP2015531397 A5 JP 2015531397A5
Authority
JP
Japan
Prior art keywords
use according
monoclonal antibody
antibody
mabp1
igg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015535742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531397A (ja
JP6460993B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062903 external-priority patent/WO2014055544A1/en
Publication of JP2015531397A publication Critical patent/JP2015531397A/ja
Publication of JP2015531397A5 publication Critical patent/JP2015531397A5/ja
Application granted granted Critical
Publication of JP6460993B2 publication Critical patent/JP6460993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015535742A 2012-10-04 2013-10-01 血管疾患及びその合併症の処置 Active JP6460993B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709754P 2012-10-04 2012-10-04
US61/709,754 2012-10-04
PCT/US2013/062903 WO2014055544A1 (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Publications (3)

Publication Number Publication Date
JP2015531397A JP2015531397A (ja) 2015-11-02
JP2015531397A5 true JP2015531397A5 (enExample) 2016-11-17
JP6460993B2 JP6460993B2 (ja) 2019-01-30

Family

ID=50432830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015535742A Active JP6460993B2 (ja) 2012-10-04 2013-10-01 血管疾患及びその合併症の処置

Country Status (12)

Country Link
US (3) US20140099321A1 (enExample)
EP (3) EP3524621A1 (enExample)
JP (1) JP6460993B2 (enExample)
KR (2) KR102429919B1 (enExample)
CN (2) CN104684929A (enExample)
AU (1) AU2013327501B2 (enExample)
CA (1) CA2886747C (enExample)
HK (1) HK1211960A1 (enExample)
IL (1) IL237765B (enExample)
MX (1) MX376241B (enExample)
RU (1) RU2671955C2 (enExample)
WO (1) WO2014055544A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
NZ607472A (en) 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
MX356808B (es) 2011-09-23 2018-06-14 Xbiotech Inc Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
AU2020267329B2 (en) * 2019-05-03 2026-03-26 University Of Zurich Treatment of brain ischemia-reperfusion injury
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
KR102652849B1 (ko) 2022-03-14 2024-04-01 한국화학연구원 극성 아라미드 나노섬유로 제조한 하이드로겔

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
JP2003500069A (ja) * 1999-05-24 2003-01-07 インタールーキン ジェネティックス インク 再狭窄の診断及び治療薬
WO2003018595A2 (en) * 2001-08-24 2003-03-06 Maine Medical Center Research Institute Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
PL2285409T3 (pl) * 2008-05-30 2016-10-31 Przeciwciała il-1 alfa
BRPI1011228A2 (pt) * 2009-05-29 2019-09-24 Xoma Technology Ltd. métodos para reduzir um evento cardiovascular em um indivíduo, mortalidade seguindo um evento cardiovascular em um indivíduo e restenose em um indivíduo seguindo um procedimento de revascularização, e, para tratar um evento cardiovascular em um indivíduo e hipertensão aguda em um indivíduo.
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Similar Documents

Publication Publication Date Title
HUS2300008I1 (hu) Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
RU2015110635A (ru) Лечение сосудистого заболевания и его осложнений
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
EA201290883A1 (ru) Способы диагностики и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака
WO2016087944A3 (en) Method for treating alzheimer's disease
JP2015531396A5 (enExample)
JP2016519107A5 (enExample)
JP2013536236A5 (enExample)
de Carvalho et al. Recent advances in ophthalmic molecular imaging
Meyr et al. American College of Foot and Ankle Surgeons® clinical consensus statement: perioperative management
EP2997992A4 (en) Mechanism for guiding and/or releasing an endoprosthesis at a blood vessel lesion region, used in a medical device of the type of a cathether
IL272194A (en) Multispecific antibodies for use in treating diseases
EP2844776A4 (en) CANCER BLOOD TEST USING INSULATED BC200 RNA FROM PERIPHERAL BLOOD FOR THE DIAGNOSIS AND TREATMENT OF INVASIVE BREAST CANCER
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
JP2013094262A5 (enExample)
UA122847C2 (uk) Лікувальний комплекс для лікування діабету другого типу та діабетичної дисліпідемії
Bykov et al. Syndrome-pathogenetic Postoperational Rehabilitation of Patients with Dishormonal Mastopathy
Bonten Prof. dr. Y. van der Graaf Julius Center for Health Sciences and Primary Care
赵玉洲 Anatomy of splenic flexure and surgical treatment in 52 patients with non-obstructive splenic flexure colon cancer
Pohodenko-Chudakova et al. BASIS FOR ACUPUNCTURE APPLICATION IN COMPLEX TREATMENT OF PYOINFLAMMATORY PROCESSES ACCORDING TO THE PRINCIPLES OF DEMONSTRATIVE MEDICINE
Pohodenko-Chudakova et al. BASIS FOR ACUPUNCTURE APPLICATION IN COMPLEX TREATMENT OF PYOINFLAMMATORY PROCESSES ACCORDING TO THE PRINCIPLES OF DEMONSTRATIVE MEDICINE
张承磊 The treatment strategy of special distal landing zones in endovascular repair of abdominal aortic aneurysm
CN302536694S (zh) 病人用界面组件
PL3937988T3 (pl) Kontrast MRI do zastosowania w diagnostyce wczesnych zmian w śródbłonku naczyń krwionośnych